Quarterly report [Sections 13 or 15(d)]

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.25.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 355,788 $ 379,157 $ 729,013 $ 767,645
OPERATING EXPENSE:        
Medical expense 351,350 365,171 723,393 747,228
Premium deficiency reserve (5,967) (3,397) (12,929) (2,397)
Corporate, general and administrative expense 23,295 26,610 48,294 54,011
Sales and marketing expense 151 414 332 736
Depreciation and amortization 21,083 21,693 42,135 43,232
TOTAL OPERATING EXPENSE 389,912 410,491 801,225 842,810
OPERATING LOSS (34,124) (31,334) (72,212) (75,165)
OTHER INCOME (EXPENSE):        
Interest expense, net (10,145) (5,436) (18,870) (9,692)
Mark-to-market of stock warrants 2,002 8,673 5,324 8,889
Other 583 291 901 628
TOTAL OTHER INCOME (EXPENSE) (7,560) 3,528 (12,645) (175)
LOSS BEFORE INCOME TAXES (41,684) (27,806) (84,857) (75,340)
INCOME TAX PROVISION (1,981) (968) (3,054) (3,040)
NET LOSS (43,665) (28,774) (87,911) (78,380)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST (23,303) (16,754) (47,069) (47,660)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST $ (20,362) $ (12,020) $ (40,842) $ (30,720)
NET LOSS PER SHARE (Note 9):        
Basic (in dollars per share) $ (6.23) $ (4.40) $ (12.52) $ (12.02)
Diluted (in dollars per share) $ (6.23) $ (7.37) $ (12.52) $ (15.19)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):        
Basic (in shares) 3,267 2,732 3,263 2,556
Diluted (in shares) 3,267 2,822 3,263 2,601
Capitated Revenue [Member]        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 351,724 $ 374,306 $ 721,241 $ 758,440
Other patient service revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 4,064 $ 4,851 $ 7,772 $ 9,205